Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004014 · ClinicalTrials.gov registry record · Phase 2
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00004014 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00004014, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1999-04 |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004014
The ClinicalTrials.gov registry entry for NCT00004014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00004014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004014 about?
NCT00004014 is a clinical study titled "Liposomal Doxorubicin in Treating Patients With Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00004014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 1999-04. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00004014?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004014?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.